GENERXN RESEARCH
LIVE

Serial Number

97403266

Owner

GENERXN RESEARCH CORPORATION

Attorney

Brian Chau

Filing Date

May 10, 2022

Add to watchlist:

No watchlists yet
View on USPTO

GENERXN RESEARCH Trademark

Serial Number: 97403266

GENERXN RESEARCH is a trademark filed by GENERXN RESEARCH CORPORATION on May 10, 2022. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 16 (Paper Goods), Class 18 (Leather Goods), Class 21 (Housewares), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

GENERXN RESEARCH CORPORATION

117 Osnabrook Private
Ottawa, Ontario K2J0G8 , CA

Entity Type: 03

Trademark Details

Filing Date

May 10, 2022

Registration Date

Not Registered

Goods & Services

Promotional items, namely, cups and mugs

Promotional items, namely, pens

Pharmaceutical product evaluation services; scientific research in the nature of conducting clinical trials for others, namely, the preparation, establishment, running, management and processing of clinical trials and clinical trial data; preclinical services, namely, investigation of biological and chemical material for medical purposes; testing of pharmaceuticals, namely, diagnostic, analytical, testing and monitoring services; clinical research in the field of neuroscience; scientific research, namely, conducting and analyzing clinical trials in the field of biotechnology, pharmacology, and medical research; medical research in the field of the design and conducting of clinical trials; technical consulting services in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Training clinical trial site personnel in the field of drug protocol requirements and the use of tests and rating systems for such protocol

Promotional items, namely, all-purpose carrying bags

Clinical diagnostic services, namely, diagnosis of conditions, diseases or illnesses; performing clinical diagnostic services, namely, diagnosis of predisposition for conditions, diseases or illnesses, characterizations of disease, response to therapy, patient selection, prognosis and reoccurrence; medical and healthcare services

Business management assistance and consultation for clinical trials of investigational drugs, namely, arranging for sites to perform clinical trials, arranging for the import, packaging, shipping, labeling, and distribution of drugs and measuring apparatus, placebo drugs, manuals, precursor and analytical chemicals to and from the clinical trial sites, arranging for the central collection of laboratory specimens from the clinical trial sites, preparing statistical reports resulting from the clinical trials

Filing History

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 20, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 20, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 20, 2026 CNSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 19, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 19, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 19, 2025 REAP
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Oct 27, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 24, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 24, 2025 GNSL
SUSPENSION LETTER WRITTEN
Apr 24, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Apr 23, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 27, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 27, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 27, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 29, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 29, 2024 GNSL
SUSPENSION LETTER WRITTEN
Aug 29, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2024 CRFA
ASSIGNED TO LIE
Aug 29, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 27, 2024 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Dec 28, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Dec 28, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Dec 28, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 26, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 26, 2023 GNSL
SUSPENSION LETTER WRITTEN
Jun 26, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 5, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 5, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 4, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 4, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 4, 2023 CNRT
ASSIGNED TO EXAMINER
Feb 27, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 17, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 16, 2022 NWOS
NEW APPLICATION ENTERED
May 13, 2022 NWAP